WCG acquires Vigilare International

WIRB Copernicus Group (WCG) has acquired a provider of integrated end-to-end pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry, Vigilare International.

“We are delighted to welcome Vigilare to the WCG family of companies,” said Donald A. Deieso, PhD, chairman and CEO of WCG. “With its comprehensive service suite, Vigilare provides clients with streamlined, regulatory compliant operations, faster access to safety data and focused in-depth product safety reporting and analysis. Vigilare saves clients time and money by offering them a robust alternative to building and maintaining an internal pharmacovigilance and drug safety programme.”

“WCG is a perfect fit for Vigilare,” added James A. Bannon, PharmD, president and CEO of Vigilare. “Our pharmacovigilance services are a natural complement to WCG’s existing portfolio of clinical research optimization solutions. We look forward to working with our colleagues at WCG to identify additional opportunities to streamline clinical research operations, while improving the quality of product safety information.”

WIRB-Copernicus Group (WCG) is a provider of solutions for the improvement of the quality and efficiency of clinical research.